SCHEMBL5540460

SCHEMBL5540460

[CH2]c1cccc(-c2ccccc2F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.47
PTPN1 P18031 1/20 0.47
ACMSD Q8TDX5 1/20 0.42
BACE1 P56817 1/20 0.41
TRPA1 O75762 1/20 0.41
PDK2 Q15119 1/20 0.40
KAT6A Q92794 1/20 0.39
MAP4K4 O95819 1/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
ALOX5AP P20292 2/20 0.38
FEN1 P39748 2/20 0.38
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12856837 0.84 PTPRC (0.55) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL29628986 0.84 PTPRC (0.55) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL12856709 0.82 PTPRC (0.53) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL2093620 0.78 TTR (0.39) TRPA1ALOX5APFEN1L3MBTL1NPC1
SCHEMBL30525640 0.78 PTPRC (0.50) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL29893718 0.78 PTPRC (0.50) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL780417 0.78 PTPRC (0.50) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL2135614 0.78 PTPRC (0.50) PTPRCPTPN1ACMSDBACE1TRPA1
SCHEMBL2090855 0.77 ALOX5AP (0.43) PTPRCPTPN1ALOX5APFEN1
SCHEMBL29304952 0.77 PTPRC (0.53) PTPRCPTPN1ACMSDBACE1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0020685-B1 INSECTICIDAL CYCLOPROPANECARBOXYLATES FROM SUBSTITUTED (1,1'-BIPHENYL)-3-YLMETHYL COMPOUNDS FMC Corporation (US) 1983-06-15 EP claimed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PTPRC 2098/4885PTPN1 1427/4885ACMSD 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.